Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Palisade Bio, Inc. Common Stock

PALI

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Last trade $1.01
Day change -$0.02 (-1.94%)
Day range $0.991 – $1.06
Volume 1,360,774
Market cap $185M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$184.86M
Price / earnings
—
Price / book
1.64×
Price / sales
369.72×
EV / sales
142.5×
EV / EBITDA
-1.48×

Profitability

Earnings per share
-$0.24
Return on assets
-36.86%
Return on equity
-38.86%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
20.16×
Quick ratio
20.16×
Cash ratio
19.5×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$26.4M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PALI, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$500K$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$500K$0$0$0$0$0$0
Selling, general and administrative$5.12M$4.8M$4.35M$3.81M$1.53M$1.17M$1.36M$1.3M
Research and development$10.58M$7.4M$6.4M$6.17M$1.39M$1.68M$950K$2.08M
Total operating expenses$15.7M$12.2M$10.75M$9.98M$2.92M$2.84M$2.31M$3.38M
Operating income-$15.7M-$11.7M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M
Interest expense$0$0-$1K-$2K-$5K-$2K-$1K-$3K
Income before taxes-$14.62M-$10.57M-$9.6M-$8.9M-$2.87M-$2.78M-$2.23M-$3.34M
Income taxes$0$0$0$0$0$0$0$0
Net income-$14.62M-$10.57M-$9.6M-$8.9M-$2.87M-$2.78M-$2.23M-$3.34M
Net income attributable to common shareholders-$14.62M-$10.57M-$9.6M-$8.9M-$2.87M-$2.78M-$2.23M-$3.34M
EBITDA-$15.7M-$11.7M-$10.75M-$9.98M-$2.92M-$2.84M-$2.31M-$3.38M
Basic earnings per share-$0.07-$0.05-$0.05-$0.04-$0.38-$0.58-$0.47-$1.54
Diluted earnings per share-$0.07-$0.05-$0.05-$0.04-$0.38-$0.58-$0.47-$1.54

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Palisade Bio to Present Clinical and Translational Data for PALI-2108 in Ulcerative Colitis and Crohn’s Disease at UEG Week 2026

Palisade Bio announced that its lead program PALI-2108, an oral PDE4 inhibitor prodrug, will be featured in four presentations at UEG Week 2026 in Barcelona. The presentations will showcase Phase 1b findings in fibrostenotic Crohn's disease, early clinical activity in ulcerative colitis, favorable safety and tolerability, gut-targeted exposure, and a biomarker to predict treatment response. PALI-2108 is advancing into Phase 2 clinical development for both ulcerative colitis and Crohn's disease.

GlobeNewswire Inc.

Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance

Palisade Bio announced Health Canada's clearance of its Clinical Trial Application for ASCENTRA-UC, a global Phase 2 study evaluating PALI-2108 in patients with moderately to severely active ulcerative colitis. The clearance expands the study's geographic reach alongside prior U.S. regulatory approval. The company expects to begin patient dosing in the second half of 2026, with primary efficacy results anticipated in the second half of 2027.

GlobeNewswire Inc.

Palisade Bio to Participate in Upcoming Investor Conferences

Palisade Bio, Inc. (Nasdaq: PALI), a clinical-stage biopharmaceutical company, announced that management will participate in three major healthcare investor conferences in September 2026: Wells Fargo Healthcare Conference (Sept 8-10), Morgan Stanley Global Healthcare Conference (Sept 14-16), and H.C. Wainwright Global Investment Conference (Sept 14-16). The company is advancing PALI-2108, a once-daily oral PDE4 inhibitor prodrug, into Phase 2 clinical trials for inflammatory bowel disease treatment.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Apr 8, 20241-for-15reverse split
Nov 16, 20221-for-50reverse split
Jul 18, 20191-for-20reverse split
Jan 9, 20171-for-13reverse split